90327-03-0

Basic information

• Product Name: 6-chloronicotinic acid N-oxide
• Synonyms: 6-chloronicotinic acid N-oxide;5-carboxy-2-chloropyridine 1-oxide
• CAS NO: 90327-03-0
• Molecular Formula: C₆H₄ClNO₃
• Molecular Weight: 174
• Mol File: 90327-03-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-chloronicotinic acid N-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloronicotinic acid N-oxide(90327-03-0)
• EPA Substance Registry System: 6-chloronicotinic acid N-oxide(90327-03-0)

Safety Data

• Hazardous Substances Data: 90327-03-0(Hazardous Substances Data)

Usage

General Description

6-Chloronicotinic acid N-oxide is a chemical compound with the formula C6H3ClNO3. It is a nitrosonium salt of 6-chloronicotinic acid and is used as a building block in organic synthesis. The compound has a pale yellow color and is soluble in water. 6-Chloronicotinic acid N-oxide can be used as a reagent in the synthesis of pharmaceuticals and agrochemicals, as well as in the preparation of metal-organic frameworks. It has been studied for its potential biological activity and has shown to possess antimicrobial properties. Additionally, it has been investigated for its potential use as a corrosion inhibitor and as a catalyst in organic reactions.

Upstream product

• 73781-91-6 6-Chloronicotinic acid methyl ester 
• 677763-16-5 methyl 6-chloropyridine-3-carboxylate 1-oxide 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 

Downstream Products

• 364078-26-2 6-chloro-N-(4-fluoro-phenyl)-1-oxy-nicotinamide 

Relevant articles and documents

Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by Rational Target-Focused Repurposing Approaches

In academia, compound recycling represents an alternative drug discovery strategy to identify new pharmaceutical targets from a library of chemical compounds available in house. Herein we report the application of a rational target-based drug-repurposing approach to find diverse applications for our in-house collection of compounds. The carbonic anhydrase (CA, EC 4.2.1.1) metalloenzyme superfamily was identified as a potential target of our compounds. The combination of a thoroughly validated docking screening protocol, together with in vitro assays against various CA families and isoforms, allowed us to identify two unprecedented chemotypes as CA inhibitors. The identified compounds have the capacity to preferentially bind pathogenic (bacterial/protozoan) CAs over human isoforms and represent excellent hits for further optimization in hit-to-lead campaigns.

NEW COMPOUNDS

The present invention relates to new compounds of formula Ia or Ib wherein P represents a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected independently from N, O and S of which at least one heteroatom is nitrogen; R is hydrogen; R is selected from: C1-6alkyl, cyano, halogen, (CO)OR, and CONRR; R is selected from: C1-6alkyl, cyano, nitro, (CO)OR, C1-6alkylNRR, OC2-6alkylNRR, CONRR, and (SO2)NRR; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3 or 4; as a free base or a salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

Nicotinamide N-oxides as CXCR2 antagonists

A series of nicotinamide N-oxides was synthesized and shown to be novel, potent, and selective antagonists of the CXCR2 receptor. Furthermore, these compounds showed significant functional activity against GRO-α-driven human neutrophil chemotaxis. Compounds of this class may be useful for the treatment of inflammatory, auto-immune, and allergic disorders.